Goldman Sachs initiates coverage on Pharmasset (NASDAQ: VRUS) with a Neutral rating and $44 price target.
This article: 79 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE